Overview

Global Gout Therapeutic Market is estimated to value over USD 2.8 billion by 2026 end and register a CAGR of over 8% during the forecast period 2019 to 2026.

Growing adoption of biologics such as Rilonacept, Canakinumab and Krystexxa have been launched in the market and the expansion in the adoption of these biologics, owing to their ability to create strong anti-inflammatory action is registered to boost the market value during the forecast time frame. In addition, a number of other drugs that are undergoing clinical trials are projected to augment the gout therapeutic market growth.

Research analysis has shown that the volume of gout has showcased significant growth in recent years. It is primarily attributed to untreated or uncontrolled metabolic disorder and exceedingly high levels of uric acid present in the body. North America is registered to have a heightened gout market due to lifestyle-related problems such as obesity, high intake of alcohol and even inflammatory illnesses. Measures have been undertaken by various nations to raise awareness regarding chronic diseases and how biologics has contributed to the treatment of gout in the populations. In fact, the acceptance of new treatments and a better awareness regarding arthritic and chronic conditions, will most likely propel the market growth.

Recommendations of various medications and therapies are given to the patients and the medications are prescribed according to the severity of the ailment. Numerous companies have boosted their investments in research and development to give way for new and improved innovations in medication.

Based on the segmentation of components, the drug type in the market for gout therapeutics has been categorized into biologics, colchicine, NSAIDS, antihyperuricemic agents (also known as urate-lowering drugs) and corticosteroids. Biologics has seen a rise in adoption and are an alternative to corticosteroids and NSAIDS, as they culminate in far more effective results. It is for this reason that the biologics segment is expected to grow and in all likelihood, gain sizable gout therapeutic market share during the forecast time frame.

Antihyperuricemic agents which are also known as urate-lowering drugs, are usually recommended as the first phase of treatment. Furthermore, the acceptance and subsequent success Target 2 Treat, entails integrating both biologic as well as synthetic urate-lowering drugs. Extensive usage of these drugs in treating gout disease have contributed to the market shares in antihyperuricemic agents and biologic segments.

In terms of the distribution channel, the market for gout therapeutics has been fragmented into online, retail and hospital pharmacies. In recent years, the segment for retail pharmacy has witnessed large shares in the market on a scale.

Major players who are controlling this market includes Teijin Pharma Limited, Horizon Pharma plc, Novartis AG, Merck & Co. Inc., Ironwood Pharmaceuticals, Inc., Grunenthal Group, JW Pharmaceutical, Takeda Pharmaceutical Company Limited, Selecta Biosciences, Inc., AstraZeneca, Regeneron Pharmaceuticals, Inc

Gout Therapeutic Market Segmentation:

By Component

• Colchicine
• Antihyperuricemic agents (Urate-Lowering Drugs)
• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Biologic Response Modifiers (Biologics)

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

    By Region

• Europe
• North America
• Asia Pacific
• Latin America
• Middle East & Africa

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the gout therapeutic market by component, by distribution channel, and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Table of Contents

1 Introduction 

1.1 Objectives of the Study 

1.2 Market Definition 

        1.2.1 Markets Covered

        1.2.2 Years Considered for the Study

1.3 Currency 

1.4 Limitations 

1.5 Stakeholders 

2 Research Methodology 

2.1 Research Approach 

2.2 Research Data 

        2.2.1 Secondary Sources

                 2.2.1.1 Key Data From Secondary Sources

        2.2.2 Primary Sources

                 2.2.2.1 Key Data From Primary Sources

                 2.2.2.2 Breakdown of Primary Interviews

2.3 Market Size Estimation 

2.4 Market Breakdown and Data Triangulation 

2.5 Research Assumptions 

3 Executive Summary 

4. Market Overview

      4.1. Introduction

              4.1.1. Component Definition

              4.1.2. Industry Evolution / Developments

      4.2.  Overview

      4.3. Market Dynamics

              4.3.1. Drivers

              4.3.2. Restraints

              4.3.3. Opportunities

      4.4. Global Gout Therapeutics Market Analysis and Forecast, 2019–2026

              4.4.1. Market Revenue Projections (US$ Mn)

      4.5. Porter’s Five Force Analysis

5. Market Outlook

      5.1.Epidemiological Overview of Gout Arthritis

      5.2.Pipeline Analysis

6. Global Gout Therapeutics Market Analysis and Forecast, by Component 

      6.1. Introduction & Definition

      6.2. Key Findings / Developments

      6.3. Global Gout Therapeutics Market Value Forecast, by Drug Type, 2019–2026

              6.3.1. Colchicine

              6.3.2. Antihyperuricemic agents (Urate-Lowering Drugs) 

              6.3.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)

              6.3.4. Corticosteroids

              6.3.5. Biologic Response Modifiers (Biologics)

      6.4. Global Gout Therapeutics Market Attractiveness, by Drug Type  

7 Global Gout Therapeutics Market Analysis and Forecast, by Distribution Channel 

      7.1. Introduction & Definition

      7.2. Key Findings / Developments

      7.3. Global Gout Therapeutics Market Value Forecast, by Distribution Channel, 2019–2026

              7.3.1. Hospital Pharmacy

              7.3.2. Retail Pharmacy

              7.3.3. Online Pharmacy

      7.4. Global Gout Therapeutics Market Attractiveness, by Distribution Channel 

8. Global Gout Therapeutics Market Analysis and Forecast, by Region

      8.1. Key Findings

      8.2. Global Gout Therapeutics Market Value Forecast, by Region

              8.2.1. North America 

              8.2.2. Europe 

              8.2.3. Asia Pacific 

              8.2.4. Latin America 

              8.2.5. Middle East & Africa 

      8.3. Global Gout Therapeutics Market Attractiveness, by Country/Region

9. Competition Landscape

      9.1. Company Profiles

              9.1.1. Takeda Pharmaceutical Company Limited

                         9.1.1.1. Company Overview (HQ, Business Segments, Employee Strengths)

                         9.1.1.2 Product Portfolio

                         9.1.1.3. SWOT Analysis 

                         9.1.1.4. Strategic Overview

                         9.1.1.5. Financial Overview

              9.1.2. Teijin Pharma Limited

                         9.1.2.1. Company Overview (HQ, Business Segments, Employee Strengths)

                         9.1.2.2 Product Portfolio

                         9.1.2.3. SWOT Analysis 

                         9.1.2.4. Strategic Overview

              9.1.3. Novartis AG

                         9.1.3.1. Company Overview (HQ, Business Segments, Employee Strengths)

                         9.1.3.2 Product Portfolio

                         9.1.3.3. SWOT Analysis 

                         9.1.3.4. Strategic Overview

                         9.1.3.5. Financial Overview

              9.1.4. Mylan N.V.

                         9.1.4.1. Company Overview (HQ, Business Segments, Employee Strengths)

                         9.1.4.2 Product Portfolio

                         9.1.4.3. SWOT Analysis 

                         9.1.4.4. Strategic Overview

                         9.1.4.5. Financial Overview

              9.1.5. Horizon Pharma plc.

                         9.1.5.1. Company Overview (HQ, Business Segments, Employee Strengths)

                         9.1.5.2 Product Portfolio

                         9.1.5.3. SWOT Analysis 

                         9.1.5.4. Strategic Overview

                         9.1.5.5. Financial Overview

              9.1.6. Teva Pharmaceutical Industries Ltd.

                         9.1.6.1. Company Overview (HQ, Business Segments, Employee Strengths)

                         9.1.6.2 Product Portfolio

                         9.1.6.3. SWOT Analysis 

                         9.1.6.4. Strategic Overview

                         9.1.6.5. Financial Overview

              9.1.7 Hikma Pharmaceuticals PLC

                         9.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)

                         9.1.7.2 Product Portfolio

                         9.1.7.3. SWOT Analysis 

                         9.1.7.4. Strategic Overview

                         9.1.7.5. Financial Overview

              9.1.8. Iroko Pharmaceuticals, LLC 

                         9.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)

                         9.1.7.2 Product Portfolio

                         9.1.7.3. SWOT Analysis 

                         9.1.7.4. Strategic Overview

              9.1.9. MERCK & CO., Inc.

                         9.1.9.1. Company Overview (HQ, Business Segments, Employee Strengths)

                         9.1.9.2 Product Portfolio

                         9.1.9.3. SWOT Analysis         

                         9.1.9.4. Strategic Overview

                         9.1.9.5. Financial Overview

Chapter 10 Research Finding and Conclusion

Chapter 11 Research Methodology

Chapter 12 Research Data Source

Tables

Figures